MRVL — Marvel Biosciences Income Statement
0.000.00%
Last trade - 00:00- CA$4.70m
- CA$6.35m
Annual income statement for Marvel Biosciences, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 0.014 | 3.16 | 2.55 | 2.41 | 1.39 |
| Operating Profit | -0.014 | -3.16 | -2.55 | -2.41 | -1.39 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.011 | -3.04 | -2.55 | -2.29 | -1.65 |
| Net Income After Taxes | -0.011 | -3.04 | -2.55 | -2.29 | -1.65 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.011 | -3.04 | -2.55 | -2.29 | -1.65 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.011 | -3.04 | -2.55 | -2.29 | -1.65 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.172 | -0.078 | -0.058 | -0.041 |
| Dividends per Share |